The DOCK2 Knockout A-549 Polyclonal Cells product consists of a heterogeneous pool of A-549 cells engineered via CRISPR/Cas9-mediated disruption of the DOCK2 locus. This polyclonal knockout cell population provides a loss-of-function model to investigate DOCK2-dependent cellular processes without single-cell clonal selection. The polyclonal nature preserves genetic diversity at the edited site, offering a robust tool for functional studies where clonal artifacts are undesirable.
The parental A-549 cell line is a human lung adenocarcinoma epithelial model originally derived from a 58-year-old male patient. These cells exhibit characteristics of alveolar type II pneumocytes and are extensively employed in cancer biology, drug discovery, and respiratory disease research. Their adherent growth and robust proliferation make them suitable for a wide range of molecular and cellular assays.
DOCK2 is a Rac guanine nucleotide exchange factor (GEF) critical for cytoskeletal reorganization and cell migration. It is activated downstream of chemokine receptors (e.g., CXCR4, CCR7), integrins, and the T/B cell receptor complex, often in conjunction with PI3K-generated phosphoinositides (PI(3,4,5)P3). DOCK2 forms a complex with ELMO1/ELMO2, CRK, and Nck, leading to the activation of Rac1 and Rac2 GTPases. Activated Rac then stimulates PAK kinases and the WAVE regulatory complex, which together promote Arp2/3-mediated actin polymerization and lamellipodia formation. This signaling cascade also triggers JNK and p38 MAPK pathways, linking cytoskeletal dynamics to gene expression. In immune cells, DOCK2 is indispensable for lymphocyte homing and immune synapse assembly.
In A-549 lung adenocarcinoma cells, DOCK2-dependent Rac signaling supports the migratory and invasive properties linked to metastatic potential. Disruption of DOCK2 expression impairs chemokine-directed motility, reduces actin-based protrusions, and attenuates invasiveness through extracellular matrix barriers. Consequently, this polyclonal knockout model provides a powerful system to investigate how cytoskeletal dynamics governed by Rac contribute to lung cancer progression and metastasis.
Typical applications include Transwell migration and invasion assays, actin cytoskeleton staining, GTPase pull-down assays for Rac activation, and phospho-PAK immunoblotting. RT-qPCR can monitor downstream transcriptional changes, and flow cytometry enables profiling of chemokine receptor expression. These knockout cells support drug target validation for anti-metastatic compounds and facilitate studies of tumor-immune cell interactions in the lung microenvironment. For further information, contact Ascent Research.
